CN113811534B - Tyk2抑制剂和其用途 - Google Patents

Tyk2抑制剂和其用途 Download PDF

Info

Publication number
CN113811534B
CN113811534B CN202080034800.9A CN202080034800A CN113811534B CN 113811534 B CN113811534 B CN 113811534B CN 202080034800 A CN202080034800 A CN 202080034800A CN 113811534 B CN113811534 B CN 113811534B
Authority
CN
China
Prior art keywords
alkyl
heterocycloalkyl
optionally substituted
compounds
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080034800.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN113811534A (zh
Inventor
B·靳
Q·董
G·洪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arumis
Esk Therapy Co ltd
Original Assignee
Arumis
Esk Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arumis, Esk Therapy Co ltd filed Critical Arumis
Publication of CN113811534A publication Critical patent/CN113811534A/zh
Application granted granted Critical
Publication of CN113811534B publication Critical patent/CN113811534B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202080034800.9A 2019-03-11 2020-03-10 Tyk2抑制剂和其用途 Active CN113811534B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962816698P 2019-03-11 2019-03-11
US62/816,698 2019-03-11
US201962835376P 2019-04-17 2019-04-17
US62/835,376 2019-04-17
US201962877741P 2019-07-23 2019-07-23
US62/877,741 2019-07-23
US201962931119P 2019-11-05 2019-11-05
US62/931,119 2019-11-05
PCT/US2020/021850 WO2020185755A1 (en) 2019-03-11 2020-03-10 Tyk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
CN113811534A CN113811534A (zh) 2021-12-17
CN113811534B true CN113811534B (zh) 2024-10-29

Family

ID=72427699

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080034800.9A Active CN113811534B (zh) 2019-03-11 2020-03-10 Tyk2抑制剂和其用途

Country Status (10)

Country Link
US (2) US20220177486A1 (enExample)
EP (1) EP3938369A4 (enExample)
JP (1) JP7586829B2 (enExample)
KR (1) KR102899985B1 (enExample)
CN (1) CN113811534B (enExample)
AU (1) AU2020239026B2 (enExample)
BR (1) BR112021017996A2 (enExample)
CA (1) CA3132632A1 (enExample)
IL (1) IL286248B2 (enExample)
WO (1) WO2020185755A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66346B1 (sr) 2018-10-22 2025-01-31 Alumis Inc Inhibitori tyk2 i njihova upotreba
SG11202110523XA (en) * 2019-03-26 2021-10-28 Ventyx Biosciences Inc Tyk2 pseudokinase ligands
US12410191B2 (en) 2019-05-21 2025-09-09 Zhejiang Hisun Pharmaceutical Co., Ltd. Macrolide derivatives, preparation method and application thereof
CN114929226B (zh) 2019-11-08 2024-09-27 温缇克斯生物科学公司 Tyk2假激酶配体
IL301385A (en) * 2020-09-16 2023-05-01 Alumis Inc TYK2 inhibitors and their use
WO2022117090A1 (zh) * 2020-12-03 2022-06-09 成都科岭源医药技术有限公司 一种多环化合物及其制备方法和用途
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
CN119487037A (zh) * 2022-03-16 2025-02-18 阿鲁米斯股份有限公司 Tyk2抑制剂及其用途
EP4493281A1 (en) * 2022-03-16 2025-01-22 Alumis Inc. Tyk2 inhibitors and uses thereof
WO2023208244A1 (zh) * 2022-04-29 2023-11-02 南京明德新药研发有限公司 大环类化合物及其应用
EP4692096A4 (en) 2023-03-31 2026-07-22 Prime Gene Therapeutics Co Ltd MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND ITS USE
WO2024222807A1 (en) * 2023-04-27 2024-10-31 Hangzhou Highlightll Pharmaceutical Co., Ltd Novel macrocyclic heteroaryl derivatives as kinase inhibitors
WO2025194074A1 (en) * 2024-03-15 2025-09-18 Neuron23, Inc. Kinase modulators and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107735399A (zh) * 2015-07-02 2018-02-23 Tp生物医药公司 作为蛋白质激酶的调节剂的手性二芳基大环
CN113874021A (zh) * 2019-03-26 2021-12-31 温缇克斯生物科学公司 Tyk2假激酶配体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
ES2702126T3 (es) 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
WO2015112806A2 (en) * 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
KR102782807B1 (ko) 2015-11-18 2025-03-14 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
JOP20190092A1 (ar) * 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) * 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
PT3658148T (pt) * 2017-07-28 2024-08-26 Turning Point Therapeutics Inc Compostos macrocíclicos e utilizações dos mesmos
IL317854A (en) 2017-07-28 2025-02-01 Takeda Pharmaceuticals Co TYK2 inhibitors and their uses
CN109053682B (zh) 2018-07-27 2020-10-27 东南大学 一种tdo小分子抑制剂衍生物及其抗肿瘤偶联物和制备方法
CN114929226B (zh) 2019-11-08 2024-09-27 温缇克斯生物科学公司 Tyk2假激酶配体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107735399A (zh) * 2015-07-02 2018-02-23 Tp生物医药公司 作为蛋白质激酶的调节剂的手性二芳基大环
CN113874021A (zh) * 2019-03-26 2021-12-31 温缇克斯生物科学公司 Tyk2假激酶配体

Also Published As

Publication number Publication date
EP3938369A1 (en) 2022-01-19
IL286248A (en) 2021-10-31
JP2022524974A (ja) 2022-05-11
KR20210141973A (ko) 2021-11-23
US20250276977A1 (en) 2025-09-04
CN113811534A (zh) 2021-12-17
AU2020239026A1 (en) 2021-09-23
EP3938369A4 (en) 2023-01-25
IL286248B1 (en) 2025-08-01
AU2020239026B2 (en) 2025-10-09
CA3132632A1 (en) 2020-09-17
US20220177486A1 (en) 2022-06-09
KR102899985B1 (ko) 2025-12-15
JP7586829B2 (ja) 2024-11-19
BR112021017996A2 (pt) 2021-11-16
IL286248B2 (en) 2025-12-01
WO2020185755A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
KR102899985B1 (ko) Tyk2 억제제 및 그의 용도
CN113490664B (zh) Tyk2抑制剂和其用途
CN117279922B (zh) Tyk2抑制剂及其用途
CN115043836B (zh) 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
JP2025509596A (ja) Ｔｙｋ２阻害剤およびその使用
CN119487037A (zh) Tyk2抑制剂及其用途
HK40063819A (en) Tyk2 inhibitors and uses thereof
HK40063819B (en) Tyk2 inhibitors and uses thereof
HK40065275A (zh) Tyk2抑制剂和其用途
RU2813233C2 (ru) Ингибиторы tyk2 и пути их применения
HK40105557A (en) Tyk2 inhibitors and uses thereof
HK40105557B (en) Tyk2 inhibitors and uses thereof
HK40065275B (en) Tyk2 inhibitors and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: California, USA

Applicant after: Arumis

Address before: California, USA

Applicant before: ESK therapy Co.,Ltd.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40063819

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant